HK1029595A1 - Cyclic antagonists of c5a receptors and g protein-coupled receptors - Google Patents

Cyclic antagonists of c5a receptors and g protein-coupled receptors

Info

Publication number
HK1029595A1
HK1029595A1 HK01100346A HK01100346A HK1029595A1 HK 1029595 A1 HK1029595 A1 HK 1029595A1 HK 01100346 A HK01100346 A HK 01100346A HK 01100346 A HK01100346 A HK 01100346A HK 1029595 A1 HK1029595 A1 HK 1029595A1
Authority
HK
Hong Kong
Prior art keywords
receptors
protein
coupled receptors
coupled
cyclic antagonists
Prior art date
Application number
HK01100346A
Other languages
English (en)
Inventor
David Fairlie
Stephen Maxwell Taylor
Angela Monique Finch
Allan Wong
Original Assignee
Univeristy Of Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univeristy Of Queensland filed Critical Univeristy Of Queensland
Publication of HK1029595A1 publication Critical patent/HK1029595A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
HK01100346A 1997-06-25 2001-01-12 Cyclic antagonists of c5a receptors and g protein-coupled receptors HK1029595A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO7550A AUPO755097A0 (en) 1997-06-25 1997-06-25 Receptor agonist and antagonist
PCT/AU1998/000490 WO1999000406A1 (en) 1997-06-25 1998-06-25 CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS

Publications (1)

Publication Number Publication Date
HK1029595A1 true HK1029595A1 (en) 2001-04-06

Family

ID=3801840

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01100346A HK1029595A1 (en) 1997-06-25 2001-01-12 Cyclic antagonists of c5a receptors and g protein-coupled receptors

Country Status (12)

Country Link
US (5) US6821950B1 (xx)
EP (1) EP1017713B1 (xx)
JP (1) JP4686696B2 (xx)
AT (1) ATE377606T1 (xx)
AU (2) AUPO755097A0 (xx)
CY (1) CY1107133T1 (xx)
DE (1) DE69838678T2 (xx)
DK (1) DK1017713T3 (xx)
ES (1) ES2294816T3 (xx)
HK (1) HK1029595A1 (xx)
PT (1) PT1017713E (xx)
WO (1) WO1999000406A1 (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023186054A1 (zh) * 2022-04-02 2023-10-05 舒泰神（北京）生物制药股份有限公司 特异性识别c5a的抗体及其应用

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPQ339899A0 (en) 1999-10-13 1999-11-04 University Of Queensland, The Novel molecules
CA2418652C (en) 2000-08-10 2010-03-23 Mitsubishi Pharma Corporation Novel 3-substituted urea derivatives and medicinal use thereof
CN102050758A (zh) 2000-09-14 2011-05-11 田边三菱制药株式会社 酰胺衍生物及其制备药物的用途
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
EP1492811B1 (en) 2002-03-19 2011-09-21 Cincinnati Childrens's Hospital Medical Center Muteins of the c5a anaphylatoxin, nucleic acid molecules encoding such muteins, and pharmaceutical uses of muteins of the c5a anaphylatoxin
CA2480082A1 (en) * 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002950657A0 (en) 2002-08-08 2002-09-12 Alchemia Limited Derivatives of monosaccharides for drug discovery
AU2002951995A0 (en) 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
AU2003266858B2 (en) * 2002-10-11 2006-09-14 Vast Bioscience Pty Limited Classes of compounds that interact with GPCRs
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
WO2004035078A1 (en) * 2002-10-16 2004-04-29 The University Of Queensland Treatment of inflammatory bowel disease
AU2002952129A0 (en) * 2002-10-17 2002-10-31 The University Of Queensland Treatment of hypersensitivity conditions
AU2003902354A0 (en) * 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
AU2003902586A0 (en) * 2003-05-26 2003-06-12 The University Of Queensland Treatment of burns
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
EP1498422A1 (de) * 2003-07-17 2005-01-19 Jerini AG C5a-Rezeptor-Antagonisten
EP1797428A1 (en) * 2004-10-04 2007-06-20 Alchemia Pty Ltd Selective inhibitors
CN101107264A (zh) * 2005-01-17 2008-01-16 捷瑞尼股份公司 C5a受体拮抗剂
DE602006019948D1 (de) * 2005-03-11 2011-03-17 Potentia Pharmaceuticals Inc Koppelten rezeptors zur behandlung von makuladegeneration
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US8580735B2 (en) 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
WO2009015087A2 (en) * 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
WO2009121065A2 (en) * 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2010001222A2 (en) * 2008-07-02 2010-01-07 Saint-Gobain Performance Plastics Chaineux Framed device, seal, and method for manufacturing same
DK2894165T3 (da) 2008-11-10 2023-03-20 Alexion Pharma Inc Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
EP2525814A4 (en) * 2010-01-22 2013-09-11 Univ Louisville Res Found METHODS OF TREATING OR PREVENTING PERIODONTITIS AND PARODONTIST-RELATED DISEASES
SI2563813T1 (sl) 2010-04-30 2015-12-31 Alexion Pharmaceuticals, Inc. Protitelesa anti-C5A in postopki uporabe protiteles
AU2011276445A1 (en) * 2010-06-29 2013-02-21 Board Of Regents Of The University Of Nebraska Analogs of C5a and methods of using same
EP2468295A1 (en) 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
US10039802B2 (en) 2011-06-22 2018-08-07 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
US20150241429A1 (en) * 2012-09-11 2015-08-27 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
ES2879430T3 (es) 2012-11-15 2021-11-22 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US10092620B2 (en) * 2013-04-02 2018-10-09 The Scripps Research Institute Uses of cyclic peptides for treating and preventing atherosclerosis
BR122020019190B1 (pt) 2013-08-07 2023-11-21 Alexion Pharmaceuticals, Inc. Métodos para monitorar a responsividade de um indivíduo ao tratamento com um inibidor do complemento, métodos para diagnosticar um indivíduo tendo ou com risco de desenvolver síndrome urêmica hemolítica atípica (ahus) e uso de um kit de diagnóstico para diagnosticar ahus
ES2974107T3 (es) 2015-10-07 2024-06-25 Apellis Pharmaceuticals Inc Regímenes de dosificación
AU2017304103A1 (en) 2016-07-29 2019-01-17 Pfizer Inc. Cyclic peptides as C5 a receptor antagonists
EP3532845A1 (en) 2016-10-27 2019-09-04 Alexion Pharmaceuticals, Inc. Assay for c5b-9 deposition in complement-associated disorders
AU2018249310A1 (en) 2017-04-03 2019-10-17 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
JP2020516607A (ja) 2017-04-07 2020-06-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
WO2018234118A1 (en) 2017-06-23 2018-12-27 Inflarx Gmbh TREATMENT OF INFLAMMATORY DISEASES BY INHIBITORS OF C5A ACTIVITY
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
BR112022019090A2 (pt) 2020-03-27 2022-11-08 Inflarx Gmbh Inibidores de c5a para o tratamento de infecção por coronavírus
EP4150338A1 (en) 2020-05-15 2023-03-22 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5386011A (en) 1990-12-27 1995-01-31 Abbott Laboratories Hexapeptide anaphylatoxin-receptor ligands
AU698919B2 (en) * 1993-12-06 1998-11-12 Novartis Ag C5a receptor antagonists having substantially no agonist activity
US5807824A (en) * 1993-12-06 1998-09-15 Ciba-Geigy Corporation C5A receptor antagonists having substantially no agonist activity
US5614370A (en) * 1994-03-18 1997-03-25 Merck & Co., Inc. Assay to identify human C5a antagonists and agonists
US5696230A (en) * 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPR833401A0 (en) 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023186054A1 (zh) * 2022-04-02 2023-10-05 舒泰神（北京）生物制药股份有限公司 特异性识别c5a的抗体及其应用

Also Published As

Publication number Publication date
WO1999000406A1 (en) 1999-01-07
ES2294816T3 (es) 2008-04-01
ATE377606T1 (de) 2007-11-15
DE69838678D1 (de) 2007-12-20
EP1017713A4 (en) 2002-07-24
USRE41287E1 (en) 2010-04-27
US20060160726A1 (en) 2006-07-20
DK1017713T3 (da) 2008-02-11
CY1107133T1 (el) 2012-10-24
AUPO755097A0 (en) 1997-07-17
JP2002508767A (ja) 2002-03-19
EP1017713A1 (en) 2000-07-12
US6821950B1 (en) 2004-11-23
AU744991B2 (en) 2002-03-07
EP1017713B1 (en) 2007-11-07
US20090203760A1 (en) 2009-08-13
PT1017713E (pt) 2007-12-18
AU8092698A (en) 1999-01-19
US20130005644A1 (en) 2013-01-03
JP4686696B2 (ja) 2011-05-25
DE69838678T2 (de) 2008-10-30

Similar Documents

Publication Publication Date Title
HK1029595A1 (en) Cyclic antagonists of c5a receptors and g protein-coupled receptors
MY137457A (en) Cyclic peptides having melanocortin-4 receptor agonist activity
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
EP0766559A4 (en) CANNABINOID RECEPTOR ANTAGONISTS
DE69732490D1 (en) Monozyclische n-heterozyclische thiosäure derivate als antikoagulans
NO983431L (no) Anti-klöemidler
BG103548A (en) Vitronectine receptor antagonists
SE9704836D0 (sv) Novel receptor
TR199901710T2 (xx) IL-8 resept�r antagonistleri.
MX9805253A (es) Antagonistas del receptor de vitronectina.
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
PT813525E (pt) Derivados de benzamidina e sua utilizacao como anticoagulantes
ID23374A (id) Halogenopirimidin
MXPA06003363A (es) Derivados de fenil-piperazina como moduladores de receptores muscarinicos.
EP1244452A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
EA200000086A1 (ru) Алатрофлоксациновые парентеральные составы
AU2001245209A1 (en) Screening methods for bone morphogenetic mimetics
TR199901761T2 (xx) IL-8 resept�r antagonistleri.
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
DE60201892D1 (en) Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist
ATE279923T1 (de) Urotensin-ii rezeptorantagonisten
UA81464C2 (en) NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS
EP1117681A4 (en) NEW PEPTIDES
SE9902763D0 (sv) Novel receptor